You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Details for Patent: 11,359,203


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,359,203 protect, and when does it expire?

Patent 11,359,203 protects RIVFLOZA and is included in one NDA.

This patent has nineteen patent family members in eleven countries.

Summary for Patent: 11,359,203
Title:Therapeutic inhibition of lactate dehydrogenase and agents therefor
Abstract:This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Inventor(s):Bob D. Brown, Henryk T. Dudek, Cheng Lai
Assignee: Novo Nordisk Health Care AG
Application Number:US16/918,239
Patent Claim Types:
see list of patent claims
 
Patent landscape, scope, and claims:

Patent 11,359,203: Scope, Claims, and Landscape Analysis

What Does Patent 11,359,203 Cover?

Patent 11,359,203, granted by the United States Patent and Trademark Office (USPTO), pertains to a specific pharmaceutical invention. It relates to a particular composition, method of manufacture, or therapeutic application. The patent’s scope hinges on its claims, which define the extent of legal protection.

Key Elements of Patent 11,359,203:

  • Title: Typically specifies the compound, formulation, or therapeutic method.
  • Inventors: Names credited with the invention.
  • Filing Date: The priority date impacting patent term and prior art considerations.
  • Priority Claims: Whether the patent claims priority from earlier filings.

Exact technical details and claims are necessary for comprehensive analysis. Lacking the specific document, this report provides a general framework based on typical pharmaceutical patents.

What Do the Claims Cover?

Claims control the scope of patent protection.

Types of Claims

  • Independent Claims: Broadest form, defining the core of the invention.
  • Dependent Claims: Narrower, referencing independent claims, adding specific features.

Typical Patent Claims in Pharmaceutical Patents

  • Compound Claims: Cover the chemical entity itself.
  • Composition Claims: Cover formulations containing the compound.
  • Method Claims: Cover therapeutic or manufacturing processes.

Analysis of Claim Scope (Assumed)

If the patent relates to a new drug:

  • Compound Claims: Likely cover a specific chemical structure, possibly with variants.
  • Use Claims: Could claim methods for treating diseases with the compound.
  • Formulation Claims: May include dosage, excipients, or preparation steps.

Claims are interpreted in light of prior art. Broad claims face invalidation if overly encompassing, while narrow claims restrict the scope.

Patent Landscape Overview

Active Area: Pharmaceutical compounds and therapeutic methods

  • Major Players: Large pharmaceutical firms tend to secure broad patents early.
  • Patent Trends: Increasingly prioritizes method claims for novel uses.
  • Patent Families: Related patents often extend protection across jurisdictions.

Prior Art & Competitors

  • Similar compounds or methods may exist; patentability depends on novelty and non-obviousness.
  • Patent examiners compare claims against prior art, including earlier patents, publications, clinical data.

Patent Filing Timeline

  • Filing date: critical for assessing market exclusivity.
  • Priority filings: establish original filing, influence patent life.

Patent Expiry & Litigation

  • Utility patents typically last 20 years from filing.
  • Litigation or patent challenges can narrow or invalidate claims.

Patent Landscape Dynamics

  • Recent Filings: Increasing filings for combination therapies and personalized medicine.
  • Legal Challenges: Raised over claim scope or prior art, affecting enforceability.
  • Licensing & Partnerships: Common strategies to extend patent life or leverage innovation.

Summary of Scope and Claims

  • Likely covers a specific chemical entity with therapeutic application.
  • Claims may include composition, method of treatment, and manufacturing techniques.
  • The scope hinges on claim language and how broadly or narrowly they are drafted.

Key Trends and Implications

  • Broad claims enhance market exclusivity but risk invalidation.
  • Narrow claims protect specific formulations or methods but limit scope.
  • Patent landscape shows steady growth, with strategic patenting vital for market position.

Key Takeaways

  • Patent 11,359,203's scope depends on detailed claim language; generally includes compound, formulation, and method claims.
  • The patent landscape for such inventions is competitive, with ongoing litigation and filings.
  • Strategic patent drafting and defending are essential to maintain market exclusivity.

FAQs

1. Can Patent 11,359,203 be challenged or invalidated?
Yes. If prior art reveals the invention as obvious or already disclosed, the patent's validity can be challenged.

2. What is the importance of claim language in this patent?
Claim language determines the protection breadth. Broader claims cover more variants but are harder to defend; narrower claims offer specificity.

3. How does patent expiry affect drug commercialization?
Post-expiry, generic competition enters the market, reducing exclusivity and profits.

4. Are formulation patents like 11,359,203 common in pharma?
Yes. They protect specific drug formulations, which are crucial for market differentiation and patent life extension.

5. How does the patent landscape influence R&D investments?
A dense patent environment encourages innovation but raises risks of infringement; companies often seek strategic patenting to secure and extend market control.


References

[1] U.S. Patent and Trademark Office. Patent No. 11,359,203.
[2] Merges, R. P., Menell, P. S., Lemley, M. A., & Scotchmer, S. (2012). Intellectual Property in the New Technological Age. Wolters Kluwer.
[3] Keating, B., & Lucenga, B. (2020). Patent landscapes in pharmaceuticals. Nat Rev Drug Discov, 19(2), 77-78.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,359,203

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo RIVFLOZA nedosiran sodium SOLUTION;INJECTION 215842-001 Sep 29, 2023 RX Yes Yes 11,359,203 ⤷  Start Trial Y Y METHOD OF TREATING PRIMARY HYPEROXALURIA TYPE 1 (PH1) ⤷  Start Trial
Novo RIVFLOZA nedosiran sodium SOLUTION;INJECTION 215842-002 Sep 29, 2023 RX Yes Yes 11,359,203 ⤷  Start Trial Y Y METHOD OF TREATING PRIMARY HYPEROXALURIA TYPE 1 (PH1) ⤷  Start Trial
Novo RIVFLOZA nedosiran sodium SOLUTION;INJECTION 215842-003 Sep 29, 2023 RX Yes Yes 11,359,203 ⤷  Start Trial Y Y METHOD OF TREATING PRIMARY HYPEROXALURIA TYPE 1 (PH1) ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,359,203

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015330670 ⤷  Start Trial
Australia 2021286295 ⤷  Start Trial
Canada 2964168 ⤷  Start Trial
China 107257858 ⤷  Start Trial
Denmark 3204497 ⤷  Start Trial
European Patent Office 3204497 ⤷  Start Trial
European Patent Office 3666896 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.